Pulmonary RAGE RNAi Conjugates for Potent Gene Silencing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing RNAi agents for inhibiting RAGE gene expression are not potent or specific enough to be viable therapeutic candidates for treating RAGE-associated diseases and disorders.

Innovation Solution

Development of novel RNAi agents with specific nucleotide sequences and chemical modifications, combined with targeting ligands, to selectively inhibit RAGE gene expression, particularly in pulmonary cells, using delivery methods such as inhalation for targeted treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional RNAi agents are used to inhibit RAGE gene expression, then some level of gene suppression is achieved, but the potency and specificity are insufficient for therapeutic use

Engineering Contradiction:

Improvepotency and specificity of RAGE gene inhibitionVSAvoidviability as therapeutic candidate

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent applies local quality by introducing chemical modifications at specific positions within the RNAi agent structure. The modified nucleotide sequences contain specific chemical groups at defined locations that enhance binding affinity and specificity for RAGE mRNA, thereby improving potency and specificity without requiring complete structural redesign of the entire agent

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs composite materials by combining modified nucleotide sequences with specific chemical modifications to create hybrid RNAi agents. These composite structures integrate different functional elements (modified bases, altered backbones, conjugated groups) that work synergistically to achieve both high potency and therapeutic viability

Inventive Principle:

Principle #40Composite materials

2Reliability

If RNAi agents with high potency and specificity for RAGE are developed, then therapeutic effectiveness is improved, but the complexity of the agent structure increases

Engineering Contradiction:

Improvetherapeutic effectiveness for RAGE-associated diseasesVSAvoidnucleotide sequence and chemical modification complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by systematically varying specific parameters of the nucleotide sequences (length, composition, modification patterns at defined positions) to optimize therapeutic effectiveness. By adjusting these parameters in a controlled manner, the patent achieves high potency while managing structural complexity through defined modification schemes rather than unrestricted complexity

Inventive Principle:

Principle #35Parameter changes

3Measurement precision

If existing RNAi agents are used, then general gene suppression is achieved, but selective inhibition of RAGE expression is insufficient

Engineering Contradiction:

Improvespecificity of RAGE gene targetingVSAvoidefficiency of gene expression inhibition

Core Design Contradiction:

Measurement precisionVSProductivity

Solution Approach 1:

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs intermediaries by using modified nucleotide sequences as intermediary structures that bridge the gap between generic RNAi agents and highly specific RAGE inhibitors. These modified sequences act as mediators that provide both the structural framework for RNAi activity and the specific chemical features needed for selective RAGE targeting

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The described RNAi agents provide highly potent and efficient inhibition of RAGE gene expression, reducing inflammation and providing therapeutic benefits for a range of diseases associated with RAGE, including pulmonary and cardiovascular diseases, cancer, and inflammatory conditions.

Implementation Method 1

The RNAi agent includes a sense strand and an antisense strand that are complementary to each other and to the RAGE mRNA target sequence

Methodology Applied

Scientific EffectComplementary base pairing:

Data Source

PatentUS12486502B2RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use

Publication Date: 2025.12.02 ARROWHEAD PHARMACEUTICALS INC

AI summary

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an AGER gene. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, in vivo, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma.